Leukemia, Myeloid, Chronic-Phase Clinical Trial
Official title:
Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log
This study will evaluate the proportion of subjects with chronic myeloid leukemia chronic phase that sustain major molecular response after imatinib discontinuation. To be eligible for this protocol, the subject must have received imatinib as first line regiment for at least 3 years with sustained molecular response of 4log (RM4log) or higher for one year.
Patients will be followed for 2 years, with molecular monitoring, every month in the first
year and then every 2 months. Imatinib will be restarted if the major molecular response
(RM3log) is lost during the study or if the subject withdraw the informed consenting.
The primary objective is to measure the number of subject that sustain the major molecular
response (RM3log or BCR-ABL level below 0.1%) after 2 years of follow-up.
BCR: breakpoint cluster region
ABL: abelson murine leukemia
RM3log: major molecular response, BCR-ABL level below 0.1% (IS)
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01725204 -
Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia
|
Phase 2 | |
| Completed |
NCT00103701 -
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Completed |
NCT01856283 -
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
|
Phase 2 | |
| Completed |
NCT00048672 -
Therapy of Early Chronic Phase CML With Gleevec
|
Phase 2 | |
| Recruiting |
NCT02767063 -
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)
|
Phase 1/Phase 2 | |
| Terminated |
NCT01827930 -
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
|
Phase 3 | |
| Terminated |
NCT01488253 -
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
|
Phase 2 | |
| Withdrawn |
NCT01650467 -
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
|
N/A | |
| Completed |
NCT02888964 -
Pioglityazone and Imatinib for CML Patients
|
Phase 2 | |
| Terminated |
NCT03807479 -
Study in Patients With Chronic Leukemia
|
Phase 2 |